Royal Bank of Canada Cuts Viracta Therapeutics (NASDAQ:VIRX) Price Target to $2.00

Viracta Therapeutics (NASDAQ:VIRX) had its target price lowered by Royal Bank of Canada from $4.00 to $2.00 in a report released on Thursday,Benzinga reports. The firm currently has an outperform rating on the stock.

Separately, Leerink Partners cut shares of Viracta Therapeutics from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $5.00 to $3.00 in a research report on Friday, August 16th.

Viracta Therapeutics Trading Down 4.4 %

NASDAQ VIRX opened at $0.15 on Thursday. Viracta Therapeutics has a 52 week low of $0.13 and a 52 week high of $1.31. The stock has a market cap of $5.95 million, a price-to-earnings ratio of -0.14 and a beta of 0.72. The company has a 50-day moving average price of $0.22 and a two-hundred day moving average price of $0.43.

Viracta Therapeutics (NASDAQ:VIRX) last posted its earnings results on Wednesday, August 14th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.10. As a group, equities research analysts expect that Viracta Therapeutics will post -0.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Viracta Therapeutics stock. Stonepine Capital Management LLC bought a new position in shares of Viracta Therapeutics, Inc. (NASDAQ:VIRX) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 500,000 shares of the company’s stock, valued at approximately $116,000. Stonepine Capital Management LLC owned approximately 1.27% of Viracta Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 31.37% of the company’s stock.

About Viracta Therapeutics

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.